T-cell engagers face a structural bottleneck that conventional bispecific formats struggle to solve: pairing multiple binding domains without generating light chain mismatches that compromise manufacturability.
The HBICE® (HCAb-Based Immune Cell Engager) platform addresses this by building T-cell engagers entirely from fully human heavy-chain-only antibody (HCAb) components, removing the light chain variable from the equation altogether. This structural choice is what enables geometric configurations, affinity-tuning strategies, and a growing clinical pipeline that conventional H2L2 formats can’t easily match.
What is the HBICE® platform and how does it differ from a standard bispecific T-cell engager?
HBICE® (HCAb-Based Immune Cell Engager) is Nona Biosciences’ platform for building multispecific T-cell engagers (TCEs) entirely from fully human heavy-chain-only antibody (HCAb) binder modules rather than conventional paired heavy and light chain fragments.
Nona Biosciences has developed the HBICE® platform with fully human heavy chain-only binder discovery and development services, binders as TCE building blocks, and TCE engineering. Because each binding module is a single heavy chain domain rather than an H2L2 pair, the platform sidesteps the chain association problem entirely instead of managing it through engineering workarounds like knob-into-hole pairing or common light chain restriction.
The HBICE® platform expands the structural diversity of these multispecifics, enables multiplicity of binders within the TCE, and further de-risks manufacturing by eliminating light chain mismatching enabled by Nona Biosciences proprietary single-domain antibodies. This structural difference is what allows HBICE® to support geometries, such as 2+1 and 2+2 configurations, that are difficult to achieve reliably with conventional H2L2-based bispecific formats.
Why does chain mispairing matter so much for T-cell engager manufacturing?
Chain mispairing is the central manufacturability risk in multispecific antibodies built from conventional two-heavy, two-light chain (H2L2) architecture, because multiple heavy and light chains competing for pairing partners generate a mixture of correctly and incorrectly assembled species. Each mispaired combination reduces yield of the desired product and adds purification burden, which drives up cost of goods and complicates scale-up.
Novel advanced geometries can be explored with the use of heavy chain-only binders, which further de-risk manufacturing by eliminating any potential for light chain mismatching. By removing the light chain from every binder module, HBICE® eliminates this failure mode structurally rather than managing it downstream through engineering fixes, which is a meaningful departure from traditional bispecific engineering approaches that still depend on light chain pairing fidelity.
How does How T-cell engagers compare with compare to cell therapy approaches like CAR-T for solid tumors?
T-cell engagers offer a fundamentally simpler manufacturing and supply chain profile than cell therapies. CAR-T products show better efficacy than currently approved TCEs. However, manufacturability of CAR-T and other cell therapies remains a challenge, with immense COGs and a complex supply chain, both of which lead to low patient access of around 20% for eligible patients in the US.
This tradeoff helps explain why, since the approval of Blincyto® (blinatumomab), the first T-cell engager (TCE), in 2014, both TCEs and CAR-T therapies have gained momentum. While CAR-T therapies leverage similar underlying biology and can deliver deep, durable responses, TCEs remain the more scalable option for broad patient access. The table below summarizes the core tradeoffs:
|
Factor |
T-cell engagers (HBICE®) |
Cell therapy (CAR-T) |
|---|---|---|
|
Manufacturability |
Off-the-shelf, defined supply chain |
Complex, patient-specific manufacturing |
|
Cost of goods |
Significantly lower |
Immense |
|
Patient access |
Broader |
Around 20% of eligible US patients |
|
Chain mispairing risk |
Eliminated via HCAb format |
Not applicable to CAR-T format |
What geometric configurations does HBICE® support, and why does that matter for solid tumors?
HBICE® supports both 2+1 and 2+2 geometric configurations, and the underlying heavy-chain-only binder modules also enable entirely new architectures not achievable with conventional formats. With VH binder modules, geometric configurations become highly flexible, accommodating various application scenarios, such as high or low expression of TAA on the tumor cell.
This flexibility is critical for solid tumors, where target antigen density varies widely across tumor types and even within the same tumor. Additionally, completely new TCE geometries become possible, such as linear binder domain assembly, which facilitate fine-tuning of the distance between the T cell and the tumor cell in the immune synapse. Because the immune synapse geometry directly influences cytotoxic signaling, this level of structural control gives discovery teams a design lever that fixed H2L2 architectures do not offer.
Does CD3 binding affinity actually correlate with efficacy and cytokine release?
Binder affinity correlates with on-target cytotoxicity, but the relationship with cytokine release is more complex and not strictly proportional. 2+1 HBICE® bispecific BCMA x CD3 TCEs were produced by transient expression in mammalian host cells, followed with affinity capture purification by protein A and a polishing step. The CD3 binders contained within each of the HBICE® TCEs were of high, medium or low affinity.
As expected, the high affinity CD3 binder led to a lower EC50 than the medium and low affinity CD3 binders. However, the cytokine levels correlate with PBMC-mediated cytotoxicity, reflecting different CD3 binding affinity, though the relationship is not strictly proportional. Notably, TNF-α and IL-6 release did not correlate with CD3 affinity. The BCMA x CD3 TCE with medium affinity CD3 binder led to the lowest TNF-α release and almost no non-specific cytotoxicity to HL-60, which demonstrates that affinity tuning is not a simple dial and requires empirical optimization at each affinity tier. These findings are detailed in Nona Biosciences’ HBICE® white paper on affinity-tuned T-cell engagers.¹
Can affinity tuning actually widen the therapeutic window rather than just shifting potency?
Affinity tuning of heavy-chain-only CD3 binders can decouple cytotoxic potency from off-target cytokine release, which is the key to widening the therapeutic window. Tunability of cytotoxicity of VH-containing antibodies was demonstrated as one of the antibodies containing a VH CD3 binder showed higher EC50 than the antibody containing Fab CD3 binder and the other one showed lower EC50. Critically, only baseline cytotoxicity was observed on tumor cells that did not express the TAA, confirming target-antigen specificity was preserved across the affinity range tested.
The medium-affinity CD3 binder result described above, where cytotoxicity matched benchmark TCEs but cytokine release was substantially lower, is the clearest evidence that affinity tuning within the HCAb format can separate efficacy from toxicity rather than simply trading one for the other. This case study is published as part of Nona Biosciences’ HBICE® platform white paper.¹
What is the difference between an HCAb VH single-domain binder and a conventional Fab binder in a TCE?
An HCAb VH single-domain binder is a single heavy-chain variable domain with no paired light chain, while a conventional Fab binder retains the full heavy-and-light-chain pairing of a traditional antibody fragment. CD3 is an important target for immunotherapies, but challenging for antibody discovery. Almost all binder modules currently in use are based on conventional heavy chain and light chain binder modules.
The use of heavy chain-only binder modules within TCE opens up brand new avenues for TCE design and geometry. This is a common point of confusion for buyers new to the format: HCAb-derived single domains are not the same as camelid-derived VHH nanobodies from immunized llamas, even though both are single-domain formats.
Nona’s HCAb-derived single domains originate from Harbour Mice® (transgenic mice engineered to produce fully human heavy-chain-only antibodies), meaning the sequence is fully human from the outset rather than requiring humanization of a non-human scaffold.
What clinical-stage programs use HBICE® architecture today?
Several HBICE® programs have advanced from discovery into clinical and regulatory stages, spanning both 2+1 and 2+2 geometries. Project 7020, targeting BCMA x CD3 in a 2+1 HBICE® format, has reached NMPA Clearance, while other programs in the portfolio span B7H4 x CD3 (preclinical), B7H4 x 4-1BB (Phase I), PDL-1 x CD28 (discovery), ROR1 x NKp30 (discovery), and PDL1 x CD40 (IND enabling). This spread across discovery, IND-enabling, Phase I, and regulatory clearance stages demonstrates that the HBICE® format is not a theoretical construct but an architecture with an active track record moving through the clinical pipeline.
When should a discovery team choose HBICE® over a conventional bispecific format?
HBICE® is the right choice when a program needs multiplex binder geometries, cynomolgus cross-reactive CD3 binders, or freedom from light chain mismatching risk during scale-up. Nona Biosciences HBICE® platform opens up versatility of TCE geometries with heavy chain-only binder discovery and development services, off-the-shelf CD3 binders, with cynomolgus cross-reactivity and bi/multispecific antibody engineering and production.
Teams should specifically consider HCAbs from Harbour Mice® when the target biology calls for 2+2 or higher-order geometries, when TAA density varies across patient populations, or when prior programs have stalled due to light chain pairing artifacts during process development. For solid tumor indications in particular, where antigen heterogeneity is common, the geometric flexibility of the HBICE® platform provides more design options than fixed H2L2 bispecific scaffolds.
How does Nona’s Hu-mAtrIx™ platform factor into HBICE® candidate selection?
Nona Biosciences’ Hu-mAtrIx™ (Nona’s AI platform for antibody lead selection and developability optimization) extends HCAb discovery by guiding the incorporation of developability-optimized sequences into candidate binder modules. This matters for HBICE® programs because every additional binder domain in a 2+2 or higher-order geometry compounds developability risk if any single domain has poor expression, stability, or aggregation behavior. Screening binder modules through Hu-mAtrIx™ before they enter TCE assembly reduces the chance that a promising CD3 or TAA binder fails downstream during scale-up, a risk that grows with the structural complexity multispecific formats introduce.
Solid tumor T-cell engager programs that need geometric flexibility, cynomolgus cross-reactive CD3 binders, and manufacturability free of light chain mismatch risk can explore Nona’s bispecific and multispecific antibody engineering services alongside the underlying HCAb technology platform to evaluate fit for a specific target pair and tumor indication.
-
Nona Biosciences, Overcoming challenges in T Cell engagers with affinity-tuned, structurally versatile HBICE® multispecific antibodies (White Paper), 2026. Link
-
Baeuerle P.A., Reinhardt C., Bispecific T-cell engaging antibodies for cancer therapy, Cancer Research, 2009. Link
-
Klein C. et al., The present and future of bispecific antibodies for cancer therapy, Nature Reviews Drug Discovery, 2021. Link
-
Zhukovsky E.A. et al., Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection, Current Opinion in Immunology, 2016. Link
-
Middelburg J. et al., Overcoming challenges for CD3-bispecific antibody therapy in solid tumors, Cancers, 2021. Link
-
Muyldermans S., Nanobodies: natural single-domain antibodies, Annual Review of Biochemistry, 2013. Link
-
Brinkmann U., Kontermann R.E., The making of bispecific antibodies, mAbs, 2017. Link
-
Labrijn A.F. et al., Bispecific antibodies: a mechanistic review of the pipeline, Nature Reviews Drug Discovery, 2019. Link
-
Nisonoff A., Rivers M.M., Recombination of a mixture of univalent antibody fragments of different specificity, Archives of Biochemistry and Biophysics, 1961. Link
